First Bottled Green Tea to Meet the National Cancer Institute's Standard Required for Anti-cancer Benefits

TeaForHealth(R) will present the only green tea product with a qualified health claim from the U.S. Food and Drug Administration (FDA), based on the de facto standard recommended by the National Cancer Institute (NCI) for effectiveness against cancer, which is 800 ml (27 oz) of green tea containing 710 mcg/ml (-) epigallocatechin gallate (EGCG) per day in an adult. The new TeaForHealth 710EGCG(TM) organic green tea "inabottle(TM)" product, in four ready-to-drink flavors, will be made available for tasting at the Summer Fancy Food Show.
What: Dr. Lee's TeaForHealth shares the high-antioxidant 710EGCG organic green tea inabottle -- the only green tea granted an FDA qualified health claim -- with Food Lovers at the NY Summer Fancy Food Show. Preceeding the show on July 8, 2006, Dr. Lee will be available to show the attendees how to properly brew and drink green tea for its health benefits, and to answer questions about the FDA qualified health claim. On July 10, 2006, Sin Hang Lee, M.D. will present the scientific evidence upon which the FDA granted the qualified health claim, entitled, "Green Tea as Medicine to Fight Cancer," to the International Union Against Cancer (UICC) quadrennial World Cancer Congress, in Washington, D.C.

Read more

Click Following

http://www.foodingredientsfirst.com/newsmaker_article.asp?idNewsMaker=11340&fSite=AO545&next=1

Breast Cancer Prevention Drug a Possibility

A drug that treats osteoporosis has also been found to be effective in preventing breast cancer. The results are published in this week's Journal of the American Medical Association.

Older women may soon have another option in the fight against breast cancer. New studies show that Raloxifene, a drug used to treat osteoporosis, may also be effective in reducing the risk of breast cancer.

Dr. Victor Vogel and his colleagues at the University of Pittsburgh studied nearly 20,000 women with a high risk of breast cancer, who had already reached menopause. Vogel said, “What we found was that the osteoporosis drug, Raloxifene, was equally effective as the breast cancer drug, Tamoxifene, at reducing the risk of life-threatening breast cancer.”

There are side effects to both drugs. Dr. Stephanie Land researched the quality-of-life issues associated with the two drugs. The studies appear in the Journal of the American Medical Association. She said, "What women are telling us is that although there are side effects with both of these treatments, the side effects did not impact the overall quality of life in a negative way."


Read more

Click following

http://www.voanews.com/english/2006-06-23-voa39.cfm